In the last trading session, 4.74 million Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares changed hands as the company’s beta touched 0.36. With the company’s per share price at $7.05 changed hands at $0.38 or 5.70% during last session, the market valuation stood at $1.52B. RXRX’s last price was a discount, traded about -137.59% off its 52-week high of $16.75. The share price had its 52-week low at $4.54, which suggests the last value was 35.6% up since then. When we look at Recursion Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 5.49 million shares, with the 3-month average coming to 3.69 million.

Analysts gave the Recursion Pharmaceuticals Inc (RXRX) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.14. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended RXRX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Recursion Pharmaceuticals Inc’s EPS for the current quarter is expected to be -$0.44.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information

Instantly RXRX was in green as seen at the end of in last trading. With action 29.12%, the performance over the past five days has been green. The jump to weekly highs of 7.77 on Friday, 11/17/23 added 5.70% to the stock’s daily price. The company’s shares are showing year-to-date downside of -8.56%, with the 5-day performance at 29.12% in the green. However, in the 30-day time frame, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 16.53% up. Looking at the short shares, we see there were 33.05 million shares sold at short interest cover period of 12.95 days.

The consensus price target for the stock as assigned by Wall Street analysts is $15.57, meaning bulls need an upside of 54.72% from its current market value. According to analyst projections, RXRX’s forecast low is $9.00 with $35.00 as the target high. To hit the forecast high, the stock’s price needs a -396.45% plunge from its current level, while the stock would need to soar -27.66% for it to hit the projected low.

Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts

Data shows that the Recursion Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 9.64% over the past 6 months, a -22.79% in annual growth rate that is considerably lower than the industry average of 11.30%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Recursion Pharmaceuticals Inc will fall -41.90%, while the growth in revenue is estimated to hit -29.40% for the next quarter. Year-over-year growth is forecast to reach 36.20% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $20.53 million. 3 analysts are of the opinion that Recursion Pharmaceuticals Inc’s revenue for the quarter ending Mar 2024 will be $12.9 million. The company’s revenue for the corresponding quarters a year ago was $13.68 million and $12.13 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 50.10%. The estimates for the next quarter sales put growth at 6.30%.

The 2023 estimates are for Recursion Pharmaceuticals Inc earnings to decrease by -18.20%, but the outlook for the next 5-year period is at 12.00% per year.

RXRX Dividends

Recursion Pharmaceuticals Inc is expected to release its next quarterly earnings report on November 09.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 6.80% of Recursion Pharmaceuticals Inc shares while 88.93% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.41%. There are 88.93% institutions holding the Recursion Pharmaceuticals Inc stock share, with Baillie Gifford and Company the top institutional holder. As of Jun 29, 2023, the company held 12.30% of the shares, roughly 25.1 million RXRX shares worth $187.48 million.

Blackrock Inc. holds the second largest percentage of outstanding shares, with 5.69% or 11.62 million shares worth $86.8 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Sep 29, 2023 were ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard U.S. Growth Fund. With 6.8 million shares estimated at $52.0 million under it, the former controlled 3.33% of total outstanding shares. On the other hand, Vanguard U.S. Growth Fund held about 1.95% of the shares, roughly 3.97 million shares worth around $34.85 million.